About Arctoris
Arctoris is a Partnership Research Organisation (PRO) that accelerates drug discovery by combining robotics, data science, and deep biological expertise to generate precise, reproducible, and AI-ready data. Founded at the University of Oxford, the company was established to solve a fundamental problem: biology has not kept pace with the scale, rigor, and data quality modern science demands. At the heart of Arctoris is Ulysses®, a fully robotic, cloud-controlled discovery platform that runs entire assay cascades across biochemistry, biophysics, cell biology, and structural biology. The platform captures every action, parameter, and datapoint in real time, producing highly reproducible, FAIR-compliant datasets at a scale and consistency conventional CROs cannot match. Arctoris operates as a true extension of partners' teams, combining world-class scientists with a data-first automation platform to design bespoke experimental strategies and solve complex biological problems collaboratively. The company recently launched a Biophysics Centre of Excellence to bridge the AI-experimentation gap in drug discovery. Arctoris serves biotech, techbio, and pharmaceutical companies, delivering data that scientists, regulators, and machine-learning systems can trust from day one.
Mission & Story
Mission
We accelerate the discovery of new medicines by combining the power of robotics, data science, and deep biological expertise to generate precise, reproducible, and AI-ready data.
Founding Story
Arctoris was founded to solve a fundamental problem in drug discovery: biology has not kept pace with the scale, rigor, and data quality modern science demands. Born out of the University of Oxford, the founders believed life sciences deserved the same industrial discipline that transformed aerospace and semiconductor manufacturing. Manual workflows, fragmented data, and inconsistent quality control were holding discovery back, especially as AI and data-driven approaches became central to R&D.
Clinical Focus
Medical conditions and clinical areas addressed by Arctoris.
Who It Serves
Milestones & Awards
Recent Milestones
Launched Biophysics Centre of Excellence to bridge AI-experimentation gap in drug discovery. Acquired Eli Lilly's Life Sciences Studio automated robotic laboratory. Partnered with 310.ai to pioneer AI-designed proteins for cardiac therapy. Grew workforce by over 100%.
Awards & Recognition
Featured in Forbes, Drug Discovery World, Fierce Biotech, Labiotech, BioPharma Trend, Royal Society of Biology series. Founder Tom Fleming is 1851 Industrial Fellow at University of Oxford, Royal Academy of Engineering SME Leadership Fellow, Fellow of Royal Societies of Chemistry, Biology, Arts, and Top 100 Most Influential People in Healthcare and Life Sciences. Formic Ventures investment.
Key Partnerships
Company Details
- Headquarters
- Oxford, England, United Kingdom
- Employees
- 51-200
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Aria Pharmaceuticals
Aria Pharmaceuticals appears to be a pharmaceutical company focused on drug discovery and development. Based on the limited information available, the company operates in the pharmaceutical sector.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.